PTO/SEA (11/01)
Approved for use through 10/31/2002. OMB 0651-0032
rademark Office: U.S. DEPARTMENT OF COMMERCE

nformation unless it displays a manufacture of the commerce o Patenband Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number Complete if Known **FEE TRANSMITTAL** 09/607,602 for FY 2002 Application Number Patent fees are subject to annual recusion. Confirmation Number RECEIVED Filing Date June 30, 2000

First Named Inventor Matthew Joseph Doyle A. DeCloux Examiner Name TECH CENTER 1600/2900 1644 Group/Art Unit

TOTAL AMOUNT OF PAYMENT

(\$)920.00

Attorney Docket No. 8141

JUL 0 8 2002

METHOD OF PAYMENT (check one)	FEE CALCULATION (continued)				
1. [X] The Commissioner is hereby authorized to charge indicated	3. ADDITIONAL FEES				
fees and credit any over payments to:	Code (\$) Fee Description Fee Paid	9			
Deposit Account Number 16-2480	105 130 Surcharge-late filing fee or oath	្ន			
Deposit Account Name The Procter & Gamble Company	127 50 Surcharge-late provisional filing fee or cover sheet	7			
[K] Charge Any Additional Fee Required Under status. 37 C.F.R. §§1.16 and 1.17	139 130 Non-English specification	급			
	147 2,520 For filing a request for ex parte reexamination	7			
/	112 920* Requesting publication of SIR prior to	đ			
	Examiner's action []	8			
FEE CALCULATION	113 1,840* Requesting publication of SIR after	CENTER TOUUZSOU			
	Examiner's action	₫			
1. BASIC FILING FEE - Large Entity	115 110 Extension for reply within 1st month	٦			
	116 400 Extension for reply within 2 nd month				
Code (\$) Fee Description Fee Paid	117 920 Extension for reply within 3 rd month [x]				
101 740 Utility filing fee []	118 1,440 Extension for reply within 4th month	1			
106 330 Design filing fee []	128 1,960 Extension for reply within 5 th month				
108 740 Reissue filing fee []	119 320 Notice of Appeal []				
114 160 Provisional filing fee []	120 320 Filing a brief in support of an appeal	ľ			
	121 280 Request for oral hearing				
SUBTOTAL (1) (\$)[]	138 1,510 Petition to institute a public use proceeding				
	140 110 Petition to revive - unavoidable []				
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE - Large Entity	141 1,280 Petition to revive - unintentional				
	142 1,280 Utility issue fee (or reissue)				
Extra Fee from Fee	143 460 Design issue fee				
Claims Below Paid	122 130 Petitions to the Commissioner				
Total Claims [] $-20^{\bullet +} =$ [] x [] =[]	123 50 Petitions related to provisional applications []	1			
Indo	(37 C.F.R. 1.17(q)) 126 180 Submission of Information Disclosure Statement (1)				
Independent Claims [] - 3** = [] x [] = [] Multiple Dependent [] = []	· · · · · · · · · · · · · · · · · · ·				
** or number previously paid, if greater; For Reissues, see below	,	ļ			
of humber previously part, it greater, for recissues, see below	(37 CFR § 1.129(a)) 149 740 For each additional invention to be	i			
Code (\$) Fee Description	examined (37 CFR §1.129(b)	j			
103 18 Claims in excess of 20	179 740 Request for Continued Examination (RCE)				
102 84 Independent claims in excess of 3	169 900 Request for expedited examination []	ļ			
•	of a design application	ı			
104 280 Multiple dependent claim, if not paid	091 1280 Acceptance of unintentionally delayed claim for []	- 1			
109 84 **Reissue independent claims over original patent	priority under 35 U.S.C. 119, 120, 121, or 365 (a) or (c)				
110 18 **Reissue claims in excess of 20 & over original patent					
	Other fee (specify)				
	Other fee (specify)[]				
SUBTOTAL (2) (\$)[• Reduced by Basic Filing Fee Paid SUBTOTAL(3) (\$) [920.	.00j			

SUBMITTED BY					Complete (if applicable)	
Name (Print/Type)	Emelyn L. Hiland	•	Registration No. (Attorney/Agent)	41,501	Telephone	(513) 622-3236
Signature	amelin L.	Wilm	1		Date	June 24, 2002

WARNING: Information on this form my become public. Credit Card information abould not be Included on this form. Provide credit card Information and authorization on PTO-2038.

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



June 24, 2002

RECEIVED

JUL 0 8 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Case Docket No. 8141

COPY OF PAPERS OF JINALLY FILED

In the Application of

Inventor(s):

MATTHEW JOSEPH DOYLE, ET AL.

Serial No.:

Title:

09/607,602

June 30, 2000

Date Filed: PROMOTING WHOLE BODY HEALTH Group Art Unit: 1644

Examiner: A. DeCloux

Confirmation No. 8543

RECEIVED

SEP 14 2002

TECH CENTER 1600/2900

RESPONSE UNDER § 1.111

ASSISTANT COMMISSIONER FOR PATENTS

Washington D.C. 20231

Dear Sir:

In response to the Office Action dated December 27, 2001 and having a period for response of three months thereafter, please consider the amendments and remarks herein.

Applicants hereby petition the Commissioner under 37 CFR §1.136(a) to grant a three-month extension of time needed for timely response to the instant Office Action on the above-identified application to preserve pendency of said application. Submitted herewith is authorization to charge payment of the fees associated with this communication to Deposit Account No. 16-2480.

AMENDMENTS

In the Claims

The following amendments to the claims are herein made without prejudice.

Cancel Claim 1. Cancel Claims 5 and 6, which are withdrawn from further consideration by the Examiner.

2. A method for promoting whole body health in human and other animal subjects comprising topically administering to said subjects' oral cavity a topical oral composition comprising a safe and effective amount of a host-response modulating agent and a pharmaceutically acceptable oral carrier, wherein said host-response modulating agent is a H2-antagonist.

07/05/2002 ADSMAN1 00000104 162480

920.00 CH

09607602

01 FC:117